IL-6 Antibody (1936) [Alexa Fluor® 405] Summary

B cell stimulatory factor-2
B-cell differentiation factor
BSF-2
BSF2CTL differentiation factor
CDF
HGFHSFIFNB2Hybridoma growth factor
IFN-beta-2
IL6
IL-6
IL-6B-cell stimulatory factor 2
Interferon beta-2
interleukin 6 (interferon, beta 2)
interleukin BSF-2
interleukin-6
MGI-2A

Interleukin 6 (IL-6) is a pleiotropic alpha -helical cytokine that plays important roles in acute phase reactions, inflammation, hematopoiesis, bone metabolism, and cancer progression. IL-6 activity is essential for the transition from acute inflammation to either acquired immunity or chronic inflammatory disease. It is secreted by multiple cell types as a 22‑28 kDa phosphorylated and variably glycosylated molecule (1‑4). Mature human IL-6 is 183 amino acids (aa) in length and shares 41% aa sequence identity with mouse and rat IL-6 (5). Alternate splicing generates several isoforms with internal deletions, some of which exhibit antagonistic properties (6‑9). Human IL-6 is equally active on mouse and rat cells (10). IL-6 induces signaling through a cell surface heterodimeric receptor complex composed of a ligand binding subunit (IL-6 R) and a signal transducing subunit (gp130). IL-6 binds to IL-6 R, triggering IL-6 R association with gp130 and gp130 dimerization (11). gp130 is also a component of the receptors for CLC, CNTF, CT-1, IL-11, IL-27, LIF, and OSM (12). Soluble forms of IL-6 R are generated by both alternate splicing and proteolytic cleavage (3). In a mechanism known as trans‑signaling, complexes of soluble IL-6 and IL-6 R elicit responses from gp130-expressing cells that lack cell surface IL-6 R (3).
Trans‑signaling enables a wider range of cell types to respond to IL-6, as the expression of gp130 is ubiquitous, while that of IL-6 R is predominantly restricted to hepatocytes, leukocytes, and lymphocytes (3). Soluble splice forms of gp130 block trans‑signaling from IL-6/IL-6 R but not from other cytokines that utilize gp130 as a coreceptor (4, 13).